First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Sequire Investor Summit 2024, which is planned for January 23-25, 2024, at Condado Vanderbilt Hotel in San Juan, Puerto Rico.
Related news for (FWBI)
- First Wave BioPharma to Present at the DealFlow MicroCap Conference
- First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
- First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
- First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program